福建海西新药股份有限公司传来重磅消息——其在研药物Hx9428已正式获得美国食品药品监督管理局（FDA）授予的快速通道资格认定，适应症指向新生血管性年龄相关性黄斑变性这一棘手的眼科疾病。这一认定不仅意味着该药物有望加速研发进程，更凸显了海西新药在创新药赛道上的前瞻布局与研发实力。
福建海西新药股份有限公司传来重磅消息——其在研药物Hx9428已正式获得美国食品药品监督管理局（FDA）授予的快速通道资格认定，适应症指向新生血管性年龄相关性黄斑变性这一棘手的眼科疾病。这一认定不仅意味着该药物有望加速研发进程，更凸显了海西新药在创新药赛道上的前瞻布局与研发实力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.